Ophthalmology Department, Loudi Central Hospital, Loudi, Hunan, China.
Invest Ophthalmol Vis Sci. 2024 Oct 1;65(12):1. doi: 10.1167/iovs.65.12.1.
Our previous study indicated that exosomes derived from mouse adipose-derived mesenchymal stem cells (mADSC-Exos) alleviated the benzalkonium chloride (BAC)-induced mouse dry eye model. However, the specific active molecules in mADSC-Exos that contribute to anti-dry eye therapy remain unidentified. In this study, we aimed to investigate the efficacy and mechanisms of miR-223-3p derived from mADSC-Exos in dry eye models.
Enzyme-linked immunosorbent assay (ELISA) experiments were conducted to determine miR-223-3p derived from mADSC-Exos that exerted anti-inflammatory effects on hyperosmolarity-induced mouse corneal epithelial cells (MCECs). The therapeutic efficacy of miR-223-3p was evaluated in mice with dry eye induced by either BAC or scopolamine (Scop). Mice were randomly assigned to 5 groups: sham, model, miR-223-3p overexpression, miR-223-3p knockdown, and 0.1% pranoprofen (positive group). Post-treatment, the severity of dry eye symptoms, and the pro-inflammatory cytokine levels were assessed. The effect of miR-223-3p on silencing the target gene was verified using ELISA and dual luciferase reporter assays.
The mADSC-Exos that knocked out miR-223-3p did not reduce interleukin (IL)-6 content. Supplementing with miR-223-3p could restore the reduction of IL-6. The miR-223-3p effectively ameliorated ocular surface damage and decreased pro-inflammatory cytokines or chemokines in both BAC- and Scop-induced mouse dry eye models. Furthermore, miR-223-3p inhibited cell apoptosis. F-box and WD repeat domain-containing 7 (Fbxw7) was the potential direct target of miR-223-3p. The miR-223-3p suppressed the 3'-untranslated region of Fbxw7. The Fbxw7 knockdown suppressed hyperosmolarity-induced inflammation in MCECs.
The mADSC-derived exosomal miR-223-3p mitigates ocular surface damage and inflammation, indicating its potential as a promising treatment option for dry eye.
我们之前的研究表明,来源于小鼠脂肪间充质干细胞(mADSC)的外泌体(mADSC-Exos)减轻了苯扎氯铵(BAC)诱导的小鼠干眼症模型。然而,mADSC-Exos 中有助于干眼症治疗的特定活性分子仍未确定。在本研究中,我们旨在研究 mADSC-Exos 来源的 miR-223-3p 在干眼症模型中的疗效和机制。
酶联免疫吸附试验(ELISA)实验用于确定 mADSC-Exos 来源的 miR-223-3p 对高渗诱导的小鼠角膜上皮细胞(MCEC)的抗炎作用。通过 BAC 或东莨菪碱(Scop)诱导的干眼症模型评估 miR-223-3p 的治疗效果。将小鼠随机分为 5 组:假手术组、模型组、miR-223-3p 过表达组、miR-223-3p 敲低组和 0.1%普拉洛芬(阳性组)。治疗后,评估干眼症症状的严重程度和促炎细胞因子水平。使用 ELISA 和双荧光素酶报告基因检测验证 miR-223-3p 对靶基因的沉默作用。
敲除 miR-223-3p 的 mADSC-Exos 并未减少白细胞介素(IL)-6 的含量。补充 miR-223-3p 可以恢复 IL-6 的减少。miR-223-3p 可有效改善眼表损伤,并降低 BAC 和 Scop 诱导的小鼠干眼症模型中的促炎细胞因子或趋化因子。此外,miR-223-3p 抑制细胞凋亡。F-box 和 WD 重复域包含 7(Fbxw7)是 miR-223-3p 的潜在直接靶标。miR-223-3p 抑制了 Fbxw7 的 3'-非翻译区。Fbxw7 的敲低抑制了 MCEC 中的高渗诱导炎症。
mADSC 衍生的外泌体 miR-223-3p 减轻眼表损伤和炎症,表明其在干眼症治疗中具有潜在的应用价值。